Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338718 | 0.91 | LMNA (0.43) | ACHETDP1LMNABCHEPTGS2 | |
| SCHEMBL18253207 | 0.84 | EPHX1 (0.44) | ACHELMNASMN1; SMN2HTTBCHE | |
| SCHEMBL9069284 | 0.83 | CHRNA7 (0.40) | CHRNA7ACHETDP1LMNACASR | |
| SCHEMBL18722667 | 0.80 | SLC6A2 (0.50) | FFAR1TDP1LMNASMN1; SMN2MEN1 | |
| SCHEMBL10230188 | 0.80 | CHRM2 (0.39) | ACHELMNAGAAMEN1KMT2A | |
| SCHEMBL2219321 | 0.80 | ESR1 (0.50) | TDP1LMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7388807 | 0.80 | LMNA (0.35) | ACHELMNABCHEPTGS2 | |
| SCHEMBL13662055 | 0.80 | TSHR (0.47) | TDP1LMNAALDH1A1 | |
| SCHEMBL21949745 | 0.80 | TDP1 (0.45) | ACHETDP1LMNAGAAHTT | |
| SCHEMBL9069754 | 0.79 | MAPT (0.39) | SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3271361-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | BRISTOL MYERS SQUIBB CO (US) | 2020-04-22 | — | — | EP | disclosed |
| US-9828364-B2 | Pyrazole compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-28 | — | — | US | disclosed |
| EP-2265607-B1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-9512070-B2 | Method for producing compound containing BIS (perfluoroalkylsulfonyl) methyl group and salt thereof, and solid electrolyte membrane produced using same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20160340339-A1 | PYRAZOLE COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| WO-2016149437-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20150266816-A1 | Method for Producing Compound Containing BIS (Perfluoroalkylsulfonyl) Methyl Group and Salt Thereof, and Solid Electrolyte Membrane Produced Using Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| US-8735418-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-0523697-B1 | Color-developing compositions and their use | MITSUI TOATSU CHEMICALS (JP) | 1997-04-02 | — | — | EP | disclosed |
| EP-0268878-B1 | Salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal salts of the copolymers and color-developing sheets employing the agents | MITSUI TOATSU CHEMICALS (JP) | 1996-01-31 | — | — | EP | disclosed |
| US-5447901-A | Color-developing sheet: base material coated with composition of /a/ multivalent metal-modified salicylic acid resin formed from salicylic acid, a benzyl compound and optional styrene and /b/ analogous resin free of salicylic acid | MITSUI TOATSU CHEMICAL, INC. (JP) | 1995-09-05 | — | — | US | disclosed |
| US-5376615-A | Pressure sensitive elements containing a salicylic acid resin and a phenolic resin | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1994-12-27 | — | — | US | disclosed |
| EP-0523697-A1 | Color-developing compositions and their use | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-01-20 | — | — | EP | disclosed |
| US-5023366-A | Reacted with a benzyl halide, alcohol or ether; for pressure sensitive elements | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-06-11 | — | — | US | disclosed |
| EP-0268878-A2 | Salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal salts of the copolymers and color-developing sheets employing the agents | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340339-A1 | PYRAZOLE COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LYN | FFAR1 4230/4885CHRNA7 4734/4885ACHE 3550/4885 |
| US-20150266816-A1 | Method for Producing Compound Containing BIS (Perfluoroalkylsulfonyl) Methyl Group and Salt Thereof, and Solid Electrolyte Membrane Produced Using Same | PFAS, FRK, AFF4 | FFAR1 37/4885CHRNA7 2579/4885ACHE 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.